Tobacco in Sri Lanka: Use, Health Burden, Control, Taxation and Industry Structure

What the evidence supports

Sri Lanka’s tobacco question is a public-health and regulatory question before it is an industry question. The strongest recent national adult survey, the Global Adult Tobacco Survey (GATS) 2020, estimated that 19.4% of people aged 15 years and older currently used some form of tobacco. Within that total, 9.1% currently smoked tobacco and 13.4% currently used smokeless tobacco. These categories overlap: a person may use both.

Those figures do not describe a conventional consumer market. They describe exposure to addictive products with established health risks, regulated under domestic law and an international public-health treaty. They also show why cigarettes alone cannot represent tobacco use in Sri Lanka. Beedi and smokeless forms matter, while a 2024 school survey records use of e-cigarettes even though their lawful supply is restricted.

This correction therefore removes the original market forecast, competitive scoring, investment scenarios and corporate transformation advice. It examines what national surveys, fiscal records, legislation and method-labelled studies can support. Where a source reports a target, model, company statement or author interpretation rather than an observed fact, I say so.

Data cut-off: 14 August 2026.

From market narrative to tobacco-control review

The original publication treated uncertain market estimates as facts and regulation as a commercial obstacle. That approach was not suitable for a regulated product whose use creates health costs and whose producer disclosures may be intended to influence tax or enforcement policy. A defensible review needs a clear evidence hierarchy.

I use four categories. Observed evidence includes weighted survey estimates and recorded fiscal receipts. Institutional statements include a Party’s report on its treaty implementation. Models include attributable-cost and tax-gap calculations. First-party company disclosures can establish a company’s legal operations and reported ownership, but they do not independently establish national consumption, illicit volumes or the effect of taxation. This classification is carried through the report.

The same discipline applies to comparisons over time. GATS 2020, STEPS 2021 and GSHS 2024 do not share one denominator. A higher percentage in one cannot be read as a change from another without harmonised ages, questions, weights and fieldwork.

Survey	Population and fieldwork	Measure reported here	Estimate
GATS 2020	National household survey, age 15+; December 2019–July 2020	Current tobacco smoking	9.1%
STEPS 2021	National survey, age 18–69; April, November and December 2021	Current smoking	14.1%
GSHS 2024	Enrolled students in grades 8–12; school-based survey	Cigarette use on at least one of the past 30 days	5.7%

STEPS fieldwork was interrupted during the COVID-19 period, and its Step 1 response was 81%. GSHS had an overall response of 75.8% and excludes young people who were not enrolled or not present. GATS remains the primary adult source here because it was designed specifically for nationally representative tobacco surveillance among people aged 15 and older.

Adult tobacco use is broader than cigarette smoking

GATS selected one person from each participating household and completed 6,770 interviews, with a reported overall response of 96.9%. Its definition of “current” includes daily and less-than-daily use. The survey therefore supports prevalence estimates; it does not support the lifestyle profiles or commercial customer segments used in the earlier report.

GATS 2020 measure, age 15+	All adults	Men	Women
Current use of any tobacco	19.4%	36.2%	4.9%
Current tobacco smoking	9.1%	19.7%	Under 0.1%
Current cigarette smoking	6.2%	13.4%	Under 0.1%
Current bidi smoking	4.9%	10.5%	Under 0.1%
Current smokeless-tobacco use	13.4%	23.4%	4.9%

Daily smoking was 6.4% overall, and daily smokeless use was 10.5%. Cigarette and bidi percentages should not be added: dual use is possible. The very low reported female-smoking prevalence also deserves caution. It may reflect actual sex differences, but self-report, stigma and small numbers make precision difficult. It should not be converted into a claim that women are unaffected; women reported smokeless use and second-hand-smoke exposure.

The cessation results show demand for help without proving that support is adequate. Among current smokers, 51.6% planned to quit or were thinking about quitting, and 34.6% reported a quit attempt in the preceding 12 months. Among smokers who had visited a health-care provider during that period, 47.0% said they had been advised to quit. The equivalent advice estimate for smokeless-tobacco users was 30.6%. Advice is a process indicator, not evidence of sustained abstinence or comprehensive treatment access.

Youth evidence and newer products

The 2024 GSHS fact sheet covers students in grades 8–12, typically aged 13–17. It used a two-stage school-and-class sample and obtained 2,912 completed questionnaires. Within that surveyed population, 9.7% reported using any tobacco product during the past 30 days, 5.7% reported cigarette use and 5.0% reported e-cigarette use. The estimates for boys were 16.9%, 10.6% and 8.1% respectively; for girls they were 2.9%, 1.0% and 2.0%.

These are weighted school-student estimates, not national estimates for every young person. They also do not show where products came from or whether a transaction was lawful. The e-cigarette result is best read as an enforcement and prevention signal. It is not evidence of a recognised legal market, nor does it establish the contents of the devices used.

Health burden, second-hand smoke and the limits of burden estimates

Tobacco damages multiple organ systems and causes cancer, cardiovascular and respiratory disease. Smokeless tobacco also matters in Sri Lanka because of its use with betel-related products and its relationship with oral disease. However, a national disease count cannot be inferred by multiplying the GATS prevalence by a general risk figure. Attributable burden requires age, exposure, disease, relative-risk and mortality data.

GATS supplies direct evidence about reported second-hand-smoke exposure. Among adults who worked indoors or in enclosed areas, 16.7% reported exposure at work. Exposure at home at least monthly was 8.4%. Among people who had visited specified venues in the past 30 days, reported exposure was 25.2% in restaurants and 32.6% in cafés or tea houses, compared with 2.8% in government buildings, 1.9% in health facilities and 3.2% on public transport. These venue denominators differ and should not be treated as shares of the whole population.

Historical economic estimates help describe the order of the burden, but they are models. A Ministry of Health and WHO FCTC study estimated the direct and indirect cost attributed to tobacco in 2015 at Rs 89.37 billion. It allocated Rs 16.3 billion to tobacco-related cancers and Rs 73.0 billion to other tobacco-related noncommunicable diseases. The study excluded several components, including private general-practice and private-hospital costs, second-hand-smoke costs, enforcement, prevention and rehabilitation. It is therefore neither a current figure nor a complete social-cost account.

A peer-reviewed cancer-only study for the same year estimated US$121.2 million in smoking- and smokeless-tobacco-attributable cancer costs: US$42.1 million direct and US$79.1 million indirect. This narrower estimate uses attributable fractions and a prevalence-based cost-of-illness method. It should not be added mechanically to the broader estimate.

Published annual mortality statements also vary because they cover different years, exposures and models. Some refer to smoking; others refer to all tobacco or tobacco-related illness. I have not selected one as “the” annual death toll. The sound conclusion is that tobacco creates substantial preventable morbidity and mortality, while a precise headline total must identify its model, base year and scope.

Domestic law and treaty duties

Sri Lanka ratified the WHO Framework Convention on Tobacco Control on 11 November 2003, and the Convention entered into force for the country on 27 February 2005. Sri Lanka also acceded to the Protocol to Eliminate Illicit Trade in Tobacco Products on 8 February 2016. These commitments place price measures, smoke-free environments, packaging, advertising restrictions, cessation, surveillance and supply-chain controls within a public-health framework.

The National Authority on Tobacco and Alcohol Act No. 27 of 2006 created NATA and established the principal domestic controls. The consolidated text includes restrictions on sales to people under 21, vending machines, prescribed products, advertising, sponsorship, free distribution, packaging and smoking in areas to which the public has access. The 2015 amendment increased the prescribed pictorial and text warning area to 80% of the front and back of smoked-tobacco packages.

The regime is substantial but not without gaps or exceptions. The expert legal review maintained by Tobacco Control Laws reports that designated smoking areas remain possible in airports, larger hotels and larger restaurants; point-of-sale display remains permitted; and the law does not impose a tobacco-specific retail licence or a minimum cigarette pack size. These are secondary legal interpretations, last reviewed there in February 2024, and enforcement practice may change. They should be checked against current law before any legal conclusion.

Article 5.3 of the FCTC requires public-health policy to be protected from the tobacco industry’s commercial and other vested interests. Its implementation guidelines call for interactions to be limited to those strictly necessary for regulation, conducted transparently, and protected against partnerships, conflicts and preferential treatment. Sri Lanka’s own 2023 FCTC questionnaire reported a NATA mobile application for monitoring industry influence but answered “No” when asked whether the Article 5.3 guidelines were used. That is a Party self-report for the 2020–2023 reporting period, not an independent audit, but it records a material implementation issue.

Product categories are not interchangeable

The law and fiscal system treat tobacco products differently.

• Manufactured cigarettes are lawful subject to product, packaging, sales, advertising, smoke-free and tax controls. Their excise is differentiated by cigarette length.
• Beedi is a smoked tobacco product and remains within the Tobacco Tax Act. A tax applies to domestically manufactured sticks, but this mechanism is distinct from cigarette excise.
• Smokeless tobacco was included in the 2016 prohibited-products regulation. The primary Gazette prohibits manufacture, import, sale and offer for sale of any smokeless tobacco product or mixture containing tobacco.
• Flavoured, coloured or sweetened cigarettes containing tobacco are also prohibited from manufacture, import and sale under that regulation.
• Electronic cigarettes containing tobacco are named in the Gazette. The expert legal database reports that regulators apply the provision to all e-cigarettes, although that broader enforcement interpretation goes beyond the regulation’s literal product wording.
• Heated-tobacco products are not named expressly in the one-page regulation. Tobacco Control Laws reports that regulators interpret tobacco inserts and devices as falling within the smokeless-product prohibition. That interpretation should be attributed rather than presented as text quoted from the Gazette.

This distinction resolves an apparent contradiction. GATS records current smokeless use and GSHS records e-cigarette use, while the law restricts their supply. Prevalence measures behaviour; legislation defines permitted conduct. Neither proves effective enforcement on its own.

Taxation, affordability and revenue

Cigarette taxation is often reported as one percentage, but at least four concepts need separation: specific excise charged per 1,000 sticks, other transaction taxes such as VAT and the Social Security Contribution Levy, corporate income tax on profits, and company-reported total payments to government. Only the first is directly shown as cigarette excise in the fiscal tables.

The Ministry of Finance’s 2025 Budget, Economic and Fiscal Position Report lists the following specific excise schedule as at 31 January 2025. Its 2026 report repeats these rates as at 31 October 2025.

Cigarette length	Excise per 1,000 sticks
Not exceeding 60 mm	Rs 19,350
Over 60 mm and not exceeding 67 mm	Rs 50,150
Over 67 mm and not exceeding 72 mm	Rs 71,450
Over 72 mm and not exceeding 84 mm	Rs 81,000
Over 84 mm	Rs 90,050

These are nominal specific rates, not the total tax share of retail price. The standard VAT rate was 18%, while the SSCL generally applied at 2.5% to liable turnover; their bases and credits differ. Corporate income tax is levied on taxable company income and likewise cannot be added to a retail-price tax share. A company statement that it “contributed” a total amount may combine several categories and should remain labelled as company-reported.

Official fiscal records show that provisional excise receipts from “cigarettes and tobacco” were Rs 89.040 billion in January–October 2024, compared with Rs 99.042 billion in the same period of 2023. The accompanying narrative reports cigarette sales of 1,563 million sticks against 1,992 million, although its printed percentage change does not reconcile with those quantities. The 2025 Mid-Year Fiscal Position Report records Rs 44.023 billion for cigarettes/tobacco in January–June 2025, down 17.9% from Rs 53.624 billion a year earlier. These are period-specific provisional excise receipts, not total tobacco-sector revenue.

Beedi sits on a separate path. Gazette No. 2430/16 increased the tobacco tax on domestically manufactured beedi from Rs 2 to Rs 3 per stick, effective 2 April 2025. The different tax bases and rates matter for administration and public-health policy, but the available records do not support an exact current national beedi volume.

GATS gives a 2019–2020 affordability reference rather than a current price: the mean cost of 20 manufactured cigarettes was Rs 1,237.8, and the cost of 100 packs equalled 18.1% of GDP per capita. The mean price of 20 bidis was Rs 142.7. These survey-derived values are useful historically but should not be passed off as 2026 retail prices.

Independent analyses have estimated total cigarette tax shares, sometimes against WHO’s 75% retail-price benchmark. Their results depend on the chosen brand, price date and treatment of taxes. Without a current official reconciled calculation across the length tiers, I do not present one percentage as an observed 2026 fact.

Legal industry structure and disclosure boundaries

Ceylon Tobacco Company PLC’s 2025 annual report says that its principal operations are manufacturing, marketing and selling cigarettes. It identifies British American Tobacco PLC as the ultimate holding company through British American Tobacco International Holdings BV. The annual report’s shareholder table records BAT International Holdings BV with 84.13% and Philip Morris Brand SARL with 8.32% of issued shares at the reporting date.

These are dated company disclosures lodged through the Colombo Stock Exchange. They can support a description of legal ownership and reported operations. They cannot independently verify a national cigarette market share, retailer count, farmer population, illicit volume, health claim or policy effect. I therefore do not repeat the original report’s claimed 95% share or describe a commercial “moat”. A secondary country profile describes CTC as the only licensed cigarette manufacturer, but confirmation of current licensing belongs with the competent authority.

Beedi production and informal smokeless-product supply are structurally different from listed-company cigarette manufacture. The Tobacco Tax Act covers manufacturers, but the public sources reviewed do not provide a reconciled, current register linking all licences, output and tax receipts. This limits any confident account of legal and unrecorded production. It also means cigarette-company estimates of competing formats should not substitute for public statistics.

Article 5.3 is relevant to evidence use as well as meetings. When a company estimates illicit trade, tax effects or the prevalence of another tobacco product, the figure may serve a regulatory argument. It is not automatically false, but it needs transparent methods and independent assessment before entering public policy as fact.

Illicit trade: different methods answer different questions

The available illicit-trade evidence is a lesson in measurement, not a basis for a single dramatic percentage. A 2024 WHO South-East Asia review summarises a 2018 mixed-method study in six purposively selected Sri Lankan districts. A discarded-butt method estimated 15.6%, an empty-pack method 10.8%, and test purchasing identified illicit packs in 3% of 657 purchases. In a smoker survey, 67% said illicit products were accessible nearby or in town. The units, denominators and biases differ. The districts were not a national probability sample, and the high frequency of single-stick purchases can leave empty-pack studies without many packs to inspect.

The same WHO review presents a tax-gap exercise for 2020. Using GATS consumption assumptions, an average price, an assumed tax rate and reported revenue, it calculated a gap of approximately 0.2%: Rs 170.256 million against estimated revenue due of Rs 94.553 billion. Its authors warn that self-reported consumption may be understated and a generalised price and rate do not represent the tiered system. The result is a model under specified assumptions, not proof that the illicit share was 0.2%.

Seizures answer another question. Sri Lanka’s 2023 FCTC questionnaire reports cigarette and bidi seizures, but its latest quantities in that section relate to 2017. Seizure totals change with enforcement resources, targeting, detection and reporting. An increase may reflect more trafficking, better enforcement or both; a decrease can also have several explanations.

Company-sponsored or company-reported illicit estimates form a fourth class. They should be disclosed as claims from an interested party. I exclude them from the report’s findings unless the underlying sampling, product identification, geographic coverage and funding are available for independent review. The honest conclusion is that illicit trade exists, that measurement is difficult, and that the cited studies do not establish one current national share.

Public-health priorities supported by the record

The corrected evidence does not support advice on how a tobacco company should defend sales or diversify. It supports a smaller set of public-health priorities.

First, national surveillance should be repeated with stable instruments and published definitions. A future GATS would allow like-for-like adult comparison and should retain cigarettes, bidi, smokeless products, dual use, cessation, second-hand smoke and newer products. School-based evidence should remain clearly labelled as such and, where possible, be complemented by evidence that reaches young people outside school.

Second, cessation needs a measurable service pathway. Survey results should be linked to data on brief advice, referral, treatment availability, quit attempts and sustained outcomes. Smokeless-tobacco users require explicit inclusion rather than an assumption that a smoking-only service will meet their needs.

Third, fiscal reporting should publish product-specific quantities, rates and receipts in a form that reconciles cigarette length tiers and beedi taxation. Total-tax-share calculations should disclose their retail prices, dates and tax bases. This would improve debate without relying on industry estimates.

Fourth, illicit-trade monitoring should combine transparent probability-based pack or butt studies, administrative seizure data and tax-gap analysis. Each result should carry its sampling frame, funding, identification rules and uncertainty. Accession to the Illicit Trade Protocol creates a basis for supply-chain controls, but implementation evidence matters more than a treaty label alone.

Fifth, Article 5.3 safeguards should apply across government. Necessary interaction with regulated firms should be recorded and transparent. Corporate social-responsibility activity, voluntary partnerships and evidence supplied for policy decisions need conflict-of-interest controls.

Finally, the coexistence of product prohibitions and reported use requires enforcement evidence. Authorities need to distinguish possession or use from manufacture, import and sale; distinguish tobacco-containing devices from other nicotine products; and publish how current interpretations are applied. Clear rules are more useful than an unsupported assertion that a prohibited product is absent.

What this review does not conclude

This review does not calculate a tobacco market value, forecast demand, rank competitive forces, estimate legal or illicit market shares, or recommend investment in any company or product. It does not treat tax receipts as a net social benefit, because fiscal revenue and health costs describe different sides of public policy. It also does not infer that higher taxes caused a specified quantity of illicit trade; that causal claim would require a design that separates tax effects from enforcement, income, price-setting, product substitution and reporting changes.

The evidence supports a more restrained conclusion. Tobacco use in Sri Lanka includes cigarettes, bidi and a large smokeless component. Reported exposure is strongly concentrated among men for smoking, while women remain affected through smokeless use and second-hand smoke. Many users report quit interest. Student data show recent use of cigarettes, other tobacco and e-cigarettes. Domestic law and treaty commitments provide extensive controls, but reported exposure, prohibited-product use and implementation gaps show that legislation alone is not an outcome.

The industry-structure facts are correspondingly narrow. A listed, BAT-controlled company reports legal cigarette manufacturing and sales. Other products operate under different legal, tax and enforcement conditions. Beyond those points, current national volumes and shares require independent public data.

Sources and accountability

The source register above prioritises official surveys, legislation, Ministry of Finance records, WHO FCTC material and peer-reviewed research. The Ceylon Tobacco Company annual report is included only for its dated corporate disclosures. Historical costs, Party implementation answers, legal interpretations and illicit-trade calculations remain labelled according to what they are.

That boundary is central to this correction. A tobacco-control report should help readers distinguish observed prevalence from a projection, excise from total tax, a seizure from a market estimate, and a regulated company’s statement from independent evidence. Where the public record does not sustain a number, the responsible choice is to leave it out.